Liraglutide
An earlier daily-injection GLP-1 agonist—still used for diabetes and weight loss.
Back to all peptides
✨ real molecule sketch
On a prescription or label?
Liraglutide
GLP-1 medicines and gut peptides have distinct names—brand names, generics, and research codes.
Pharmacokinetic snapshot
Reference values from published sources—not prescribing or dosing advice. Cosmetic INCI peptides do not belong here; injectable and prescription contexts only.
- Half-life
- 0.5 days
- Typical dose range
- 0.6–3.0 mg
- Common frequency
- Daily (subcutaneous)
Source: DailyMed (Saxenda/Victoza)
Structure (cute edition)
✨ real molecule sketch
This peptide is a short chain of about 4 amino acids—think of it as a tiny protein necklace on your label.
INCI: Liraglutide · ~4 amino acids in our simplified view
FDA label data
Sourced from OpenFDA drug labels (public domain). Not medical advice.
Brand names: Liraglutide, Saxenda, Victoza
Manufacturer: Lupin Pharmaceuticals, Inc.
Indications
1 INDICATIONS AND USAGE Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus Limitations of Use: Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Li…
Warnings
WARNING: RISK OF THYROID C-CELL TUMORS WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide injection causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutid…
Research & public records
Counts and links from public databases (PubMed, ClinicalTrials.gov, Wikidata, NIH drug nomenclature). Educational only — not medical advice.
Knowledge base: pharmaceutical drug — Wikipedia
PubMed: 5479 indexed papers (search PubMed)
- Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis. · Diabetes, obesity & metabolism
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients. · Obstetrics and gynecology
- Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025. · Military medicine
- Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults. · Advances in therapy
- Hyperglycemia and systemic inflammation differentially shape immune dysregulation, tissue destruction, and microbiota in experimental periodontitis and peri-implantitis in diabetic mice. · Frontiers in immunology
- Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis. · Translational psychiatry
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. · BMJ (Clinical research ed.)
- Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis. · JAMA psychiatry
Clinical trials: 542 studies on ClinicalTrials.gov (view search)
- Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus · COMPLETED
- Comparison of Two Liraglutide Formulations in Healthy Subjects · COMPLETED
- The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients · WITHDRAWN
- Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers · COMPLETED
- Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? · UNKNOWN
- To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together · COMPLETED
- Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes · COMPLETED
- The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes · COMPLETED
ChEMBL: LIRAGLUTIDE · max phase 4.0
RxNorm names: 3 ML liraglutide 6 MG/ML Pen Injector [Victoza] (RxNav)
DailyMed labels: 22 SPLs
- LIRAGLUTIDE INJECTION [NORTHSTAR RX LLC]
- SAXENDA (LIRAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP]
- LIRAGLUTIDE INJECTION [HIKMA PHARMACEUTICALS USA INC.]
- LIRAGLUTIDE INJECTION, SOLUTION [TEVA PHARMACEUTICALS, INC.]
- LIRAGLUTIDE INJECTION [BIOCON PHARMA INC.]
- LIRAGLUTIDE INJECTION, SOLUTION [ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED]
- LIRAGLUTIDE INJECTION, SOLUTION [BIOCON PHARMA INC.]
- LIRAGLUTIDE INJECTION [TEVA PHARMACEUTICALS USA, INC.]
What brands say it does
Liraglutide was the first GLP-1 drug widely used for obesity (Saxenda). It works similarly to semaglutide but requires daily dosing and tends to produce somewhat less weight loss. Well-studied safety profile over many patient-years.
Where you’ll find it
Diabetes and weight-loss prescriptions; partially superseded by weekly GLP-1 drugs.
Other names you might see
Saxenda
Victoza
Daily GLP-1
Compare with similar peptides
Similar peptides
Educational only—not medical advice. GLP-1 drugs require a prescription; do not source medications online without a clinician.